Conducting a phase III clinical trial in children during the COVID- 19 pandemic: Experience and lessons learnt from a clinical research facility of Nepal

Author:

Chapagain Ram Hari12ORCID,Maharjan Jessica1,Adhikari Santosh1ORCID,Thapa Prabhat1,Kunwar Kshitij1,Giri Bishnu Rath1,Shrestha Nisha Jyoti12,Shrestha Anil Kumar12,Shrestha Sanjeet Kumar1,Tamang Suresh Man1,Cho Haeun3,Park Eun Lyeong3,Lee Jiyoung3,Lee Jinae3,Kim Deok Ryun3,Yang Jae Seung4,Saluja Tarun5,Wartel Anh6,Lynch Julia7,Song Katerina Rok5ORCID

Affiliation:

1. OCV-S Trial Site, Kanti Children’s Hospital, Kathmandu, Nepal

2. Department of Paediatrics, National Academy of Medical Sciences (NAMS), Kathmandu, Nepal

3. Biostatistics & Data Management Unit, International Vaccine Institute (IVI), Seoul, Korea

4. Science Unit, International Vaccine Institute (IVI), Seoul, Korea

5. Clinical, Assessment, Regulatory, Evaluation (CARE) Unit, International Vaccine Institute (IVI), Seoul, Korea

6. Europe Regional Office Director, International Vaccine Institute (IVI), Seoul, Korea

7. Cholera Program Director, International Vaccine Institute (IVI), Seoul, Korea

Funder

Bill & Melinda Gates Foundation

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference16 articles.

1. World Health Organization. WHO-director general’s opening at the media briefing on COVID-19. 2020 Mar 11 [accessed 2022 Jan 10]. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020.

2. World Health Organisation. Pneumonia of unknown cause–China. 2020 Jan 5 [accessed 2022 Jan 10]. https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en.

3. Managing clinical trials during COVID-19: experience from a clinical research facility

4. Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal

5. Ethical and Scientific Implications of the Globalization of Clinical Research

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3